Chronic Migraine

Males and Females 18 years and older

The trial is being conducted to determine the safety and effectiveness of the medication zavegepant in the possible treatment of migraines.

Eligibility

• At least 8 migraine days a month, and at least 15 headache days a month
• Migraine attacks, on average, lasting about 4 – 72 hours if untreated
• Must be able to distinguish migraine attacks from tension/cluster headaches
• Must use 2 acceptable methods of contraception to avoid pregnancy throughout the study

Trial Duration

The trial will last up to 24 weeks involving 9 visits to our office

Compensation

Participants are paid $75 per completed office appointment.